Aruna Vanikar
1*1 G.R. Doshi and K.M. Mehta Institute of Kidney Diseases & Research Centre and Dr. H.L. Trivedi Institute of Transplantation Sciences, Civil Hospital Campus, Asarwa, Ahmedabad, India.
*Corresponding Author: Corresponding author: Prof. Aruna Vanikar, Dept. of Pathology, Lab Medicine, Transfusion Services and Immunohematology, G.R. Doshi and K.M. Mehta Institute of Kidney Diseases & Research Centre and Dr. H.L. Trivedi Institute of Transplantation Sciences, Civil Hospital Campus, Asarwa, Ahmedabad, India. Email: ikdrcad1@sancharnet.in, Email:
ikdrcad1@sancharnet.in
Implication for health policy/practice/research/medical education:
Transplantation is now a well-accepted therapy for end organ failure.
However the recipients are required to take life–long immunosuppression
to prevent rejection. This leads to immunosuppression associated
morbidity in the form of viral/ fungal/ bacterial infections in addition
to causing financial burden on the system. Over a long run these
patients are at high risk to develop malignancies. In spite of all these
efforts, the graft is lost over 7-10 years to chronic graft attrition/
rejection. The only answer to this problem is “Transplant tolerance”
which means stable allograft function while maintaining third party
immune response intact in absence of rejections on no immunosuppression.
Since last 60 years transplanters across the globe are in search of
this “Mackenna’s gold”. The following editorial discusses how far have
we progressed in our search for the promised land of “Transplant
Tolerance.”
Please cite this paper as: Vanikar A. Transplantation tolerance: myth or reality? J Nephropathol. 2014; 3(1): 18-21. DOI: 10.12860/jnp.2014.04